Annual Meeting Clinical Trials Plenary Session, Sanofi presented data on tolebrutinib in patients with non-relapsing ...

MaaT Pharma has reported positive results from an interim safety analysis of its Phase IIb trial of MaaT033 in subjects ...

LifeMine Therapeutics has dosed the first subject in the Phase I trial of calcineurin inhibitor (CNi), LIFE-001.

Scientist.com has launched a new tool, Clinical Labs Navigator, for sourcing, managing, and executing services for clinical ...

After dropping the FNAIT therapy, Rallybio will prioritise another candidate that is being investigated in complement-driven diseases.